Mobile

A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctiv...

Update Il y a 4 ans
Reference: EUCTR2009-017961-52

A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Detect a dose-response of BGG492 as measured by change in seizure frequency from the 4-week baseline period (week -4 to .1) to the 4-week double-blind maintenance period (weeks 7 to 10).

Inclusion criteria

  • refractory partial-onset seizures

Links